|
Market Cap (25-Jun) $125,067,280 (1,258th) |
Close (30-Jun) $0.007 |
Volume (30-Jun) 188,484 |
Shortsold (14-May) 14,985,846 (0.14%) (426th) |
|
52w High $0.85 |
52w Low $0.350 |
P/E 10.33 |
EPS -0.07 |
ATH released this announcement to the ASX on 4 November 2021, 13:23. The announcement is marked as price sensitive, and is 4 page(s) in length and 262.43kb in size.
You can view all announcements from ATH and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATH was 0.024% short sold according to ASIC data. It was ranked the 561st most shorted stock on the ASX. It is now ranked as the 426th most shorted stock on the ASX with 0.138% of total shares short sold as of the latest reported data (14 May 2026).
| Other Recent Announcements from ATH | |
|---|---|
| Investor Presentation | 22 June 2023, 11:13 |
| ATH to present at MST Rare Diseases Rich Returns Forum | 21 June 2023, 9:52 |
| ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder | 30 May 2023, 13:32 |
| New Data Advance ATH434 as Neurodegeneration treatment | 4 November 2021, 13:23 |
| Change in substantial holding | 3 November 2021, 8:16 |
| Appendix 4C and Quarterly Cash Flow Report | 29 October 2021, 10:51 |
| Expanded ATH434 Phase 2 Clinical Development Program | 19 October 2021, 9:11 |
You must be logged in to post a reply.
Alterity Therapeutics 